NUCLIDIUM Secures CHF 79 Million for Radiopharmaceutical Platform Development

In an exciting development, NUCLIDIUM, a clinical-stage radiopharmaceutical company, has successfully completed its Series B funding round, raising CHF 79 million (EUR 84 million). This round was spearheaded by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, part of the Intesa Sanpaolo Group, and saw contributions from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, HighLight Capital, alongside existing investors. These funds are earmarked for advancing the clinical development of NUCLIDIUM’s Copper-61/Copper-67 theranostic pipeline, which targets various oncology indications. Additionally, the company plans to enhance its production and manufacturing capabilities through an expanded global network.

NUCLIDIUM's unique platform connects tumor-targeting molecules with copper isotopes—Copper-61 for diagnostics and Copper-67 for therapeutics. This approach aims to tackle current challenges in radiotheranostics, such as limited clinical efficacy and intricate manufacturing processes. Initial clinical trials using this technology have shown promising results, with superior lesion detection and higher tumor-to-background ratios compared to existing tracers.

Dr. Gary Ulaner, MD, PhD, recently presented early trials data at SNMMI 2025, underscoring the safety and potential enhanced imaging capabilities of 61Cu-NuriPro™, which could surpass current PET imaging standards. The data indicate significant clinical potential and broader applicability for the 61Cu/67Cu theranostic combination. Preliminary therapeutic data from NUCLIDIUM’s leading compounds, NuriPro™ and TraceNET™, demonstrate notable tumor-to-background ratios in conditions such as metastatic prostate cancer and neuroendocrine tumors, including breast cancer.

Dr. Leila Jaafar, CEO and Co-Founder of NUCLIDIUM, expressed enthusiasm about the progress, stating that the company is advancing its lead compounds into the next clinical phases to better diagnose and treat cancers like metastatic prostate and neuroendocrine tumors, as well as breast cancer. She emphasized that their copper-based radiotheranostics are designed for seamless integration into hospital workflows, facilitating global access to these innovative therapies. The platform also enables rapid development of new targets across a broader range of cancers, with a focus on those critical to women's health.

The fresh infusion of capital will enable NUCLIDIUM to expand its global production and manufacturing network for its diagnostics and therapeutics. The company also plans to grow its international team and bolster strategic partnerships with hospitals and academic institutions, initially focusing on Europe and North America.

In connection with the funding, new members joining NUCLIDIUM’s Board of Directors include Daniel Parera, MD, from Kurma Partners; Regina Hodits, PhD, from Angelini Ventures; and Liliana Nordbakk from Neva SGR. Tony Rosenberg, Chairman of the NUCLIDIUM Board, remarked that this significant Series B financing underscores investors' confidence in NUCLIDIUM's vision and its transformative potential in the oncology and nuclear medicine sectors. He noted that the financial support positions NUCLIDIUM to accelerate clinical development, expand global access for patients, and reinforce their commitment to innovation in precision oncology.

Daniel Parera, MD, Regina Hodits, PhD, and Liliana Nordbakk, reflecting the sentiments of all participating investors, expressed strong conviction in the future of precision medicine and NUCLIDIUM’s potential to scale as a next-generation radiopharmaceutical company, a vision shared by a robust European syndicate.

NUCLIDIUM, headquartered in Switzerland and Germany, is at the forefront of developing pioneering copper-based radiopharmaceuticals for cancer diagnosis and treatment. The company leverages copper isotopes, combining cutting-edge chemistry, clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and high-performing theranostic solutions globally. Their mission includes addressing unmet medical needs in oncology and advancing women's health initiatives.